Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey

Rui Huang¹, Jian-Gao Fan², Jun-Ping Shi³, Yi-Min Mao⁴, Bing-Yuan Wang⁵, Jing-Min Zhao⁶, Lun-Gen Lu⁷, Bi-Hui Zhong⁸, Zheng-Sheng Zou⁶, You-Qing Xu⁹, Yi-Nong Ye¹⁰, Long-Gen Liu¹¹, Lian-Jie Lin¹², Jian-Ping Li¹³, Hui-Ying Rao¹⁴* and Lai Wei¹⁴*

Abstract

Background: Health Related Quality of Life (HRQL) is a multi-dimensional construct that can comprehensively evaluate the patient’s health status, including physical, emotional, mental and social well-being. In this study, we aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on HRQL in a Chinese population.

Methods: In this national multicenter cross-sectional survey, patients with NAFLD were enrolled. Chronic Liver Disease Questionnaire (CLDQ)-NAFLD was used to qualify HRQL. Univariate and multivariate analysis were used to identify independent risk factors of HRQL.

Results: A total of 5181 patients with NAFLD from 90 centers were enrolled in this study (mean age, 43.8 ± 13.3 years; male, 65.8%). The overall CLDQ score was 5.66 ± 0.89. Multivariate logistic regression analysis showed that body mass index (BMI: HR, 1.642; 95% CI, 1.330–2.026), alanine transaminase (ALT: HR, 1.006; 95% CI, 1.001–1.011), triglyceride (HR, 1.184; 95% CI, 1.074–1.305), disease severity (HR, 3.203; 95% CI, 1.418–7.232) and cardiovascular disease (HR, 4.305; 95% CI, 2.074–8.939) were independent risk factors for overall CLDQ score. In the logistic analyses of individual domain, BMI and triglyceride were independent risk factors of all domains. ALT, disease severity, diabetes, depression and cardiovascular disease were influencing factors for the CLDQ score of several domains.

Conclusions: This national multicenter cross-sectional survey in China indicated that the HRQL in patients with NAFLD was impaired. HRQL was found to be significantly associated with sociodemographic and clinical factors. Attention should be paid to the optimally managing care of patients with NAFLD to improve their HRQL.

Keywords: Chronic liver disease questionnaire, Health-related quality of life, Non-alcoholic fatty liver disease, Risk factors

Background

Non-alcoholic fatty liver disease (NAFLD) is common chronic liver disease, which is characterized by the abnormal fat accumulation in liver without excessive alcohol intake [1]. This disease usually starts with simple steatosis, and then progress to non-alcoholic steatohepatitis (NASH) accompanied by different degrees of inflammation, with or without fibrosis, and ultimately develops to cirrhosis and hepatocellular carcinoma [2]. The global
prevalence of NAFLD based on imaging is around 25% [3, 4]. With the increasing prevalence of obesity and diabetes in China, it is estimated that the national prevalence of NAFLD is 29.2%, and the number of patients with NAFLD in China may account for half of patients with NAFLD worldwide [5].

Health Related Quality of Life (HRQL) is a multidimensional construct that can comprehensively evaluate the patient’s health status, including physical, emotional, mental and social well-being [6]. The Chronic Liver Disease Questionnaire (CLDQ) is a commonly used HRQL tool in liver disease [7, 8]. Although NAFLD is mostly asymptomatic, patients may experience fatigue, emotional health impairment, and reduced activity, which may impact their HRQL [9]. There have been some studies focusing on HRQL for patients with NAFLD [9–11]. Sayiner et al. found that patients with NAFLD had significantly lower quality of life and health utility scores than the general population [9]. Golabi et al. used population-based data to assess HRQL in patients with NAFLD and also found that NAFLD was associated with impairment of HRQL [11]. Other study showed that weight loss can significantly improve the quality of life for patients with NAFLD [12]. Besides, quality of life is found to be a good indicator of improved functioning for people with chronic conditions [13]. However, national survey on HRQL of patients with NAFLD is seriously lacking in China. Therefore, the aim of this study was to assess the impact of NAFLD on HRQL in a Chinese population, and to investigate whether variables related to sociodemographic and clinical characteristics were independently associated with HRQL, and finally to identify independent risk factors of HRQL.

Methods
Study design and sample size
This was a national multicenter cross-sectional survey of HRQL in Chinese population with NAFLD. The sample was selected via convenience sampling method and patients with NAFLD in 90 hospitals among 24 provinces in China were recruited consecutively from March 1 to August 1, 2019.

Participant
The diagnosis of NAFLD was based on the evidence of ultrasound, computed tomography (CT) and magnetic resonance imaging in 24 months or liver biopsies in 36 months. Patients at least 18 years of age were included in this study. Patients with other causes of liver injury (such as hepatitis B virus, hepatitis C virus or excess alcohol consumption [>196 g/week for males, >98 g/week for females], etc.), other causes of hepatic steatosis (such as tamoxifen or glucocorticoid), decompensated liver disease or hepatic cellular cancer, medical or psychological diseases, or impaired cognitive function were excluded in this study.

Sociodemographic variables
Gender, age, residence, marital status, occupation, education (junior school, high school, college or above) and family income (less than local average, local average or more than local average) were self-reported. Laboratory examination included triglyceride (TG) and alanine transaminase (ALT). Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Central obesity was defined as waist circumference ≥85 cm for female or ≥90 cm for male. Simple fatty liver, NASH and cirrhosis were reported or diagnosed by experienced hepatologists according to medical history and clinical examination of patients. In addition, complications (such as diabetes, hypertension, hyperlipidemia, cardiovascular disease, depression, and colon disease) were diagnosed by doctors.

Assessment of HRQL
As a fully validated disease-specific instrument, CLDQ had been developed and widely used for patients with chronic liver disease [14]. The CLDQ-NAFLD instrument was used to assess HRQL of patients with NAFLD in this study. The CLDQ-NAFLD instrument had 36 items grouped into 6 domains: abdominal symptoms, activity, emotional, fatigue, systemic symptoms, and worry. All the questions were formulated as “How much of the time” or “How often you experienced a problem”, and a 1–7 Likert scale was introduced for the responses (the score of 1 would correspond to “All of the time”, and the score of 7 to “None of the time”). The overall CLDQ score was calculated as an average of all domains. Higher score on the questionnaire was indicative of minimum symptoms and lower score indicated more pronounced symptoms [7].

Ethics
This study was approved by the Institutional Review Board of Peking University People’s Hospital (2018PHB259-01). Written informed consent was obtained from each patient.

Statistical analysis
All statistical analyses were performed by using SPSS version 23.0 (SPSS Institute, IL, USA). Continuous variables were expressed as means ± standard deviations (SD), while categorical variables were expressed as number and percentage. Student t-tests (gender, central obesity and complications) and analysis of variance (age, residence, education, family income, BMI and disease severity)
were used to compare the CLDQ score between groups. A stepwise multivariate logistic regression analysis was then used to identify the independent predictors that associate with HRQL. Statistical significance was set at \( p < 0.05 \).

**Results**

**Sociodemographic and clinical characteristics**

A total of 5181 patients with NAFLD were enrolled in this national multicenter cross-sectional survey. The sociodemographic and clinical characteristics of included patients were listed in Tables 1 and 2. Patients had a mean age of 43.8 ± 13.3 years and a mean BMI of 27.7 ± 6.0 kg/m². The majority of patients in this study were male (65.8%), central obesity (71.8%), simple fatty liver (90.0%), and had a family income reached to local average (70.5%). The mean duration of ongoing treatment was 12.9 ± 25.9 months. Among the 5181 patients, 801 (15.5%) had diabetes, 1191 (23.0%) had hypertension, 1955 (37.7%) had hyperlipidemia, 414 (8.0%) had cardiovascular disease, 135 (2.6%) had depression, and 115 (2.2%) had colon disease.

**Table 1** Sociodemographic characteristics of included patients

| Sociodemographic characteristics | Patients (n = 5181) |
|----------------------------------|--------------------|
| Age (years), Mean ± SD           | 43.8 ± 13.3        |
| Age group (n, %)                 |                    |
| 18–39 years                      | 2210 (42.6)        |
| 40–59 years                      | 2256 (43.5)        |
| ≥ 60 years                       | 715 (13.8)         |
| Gender (n, %), male/female       | 3411 (65.8)/1770 (34.2) |
| Residence (n, %)                 |                    |
| East                             | 1709 (33.0)        |
| West                             | 629 (12.1)         |
| South                            | 1539 (29.7)        |
| North                            | 1184 (22.9)        |
| Central                          | 119 (2.3)          |
| Marital status (n, %)            |                    |
| Single                           | 647 (12.5)         |
| Married                          | 4407 (85.1)        |
| Separated/divorced/widowed       | 127 (2.5)          |
| Occupation (n, %)                |                    |
| White collar                     | 2505 (48.3)        |
| Blue collar                      | 746 (14.4)         |
| Unemployed                       | 720 (13.9)         |
| Others                           | 1210 (23.4)        |
| Education (n, %), junior/high/college | 1195 (23.1)/1266 (24.4)/2720 (52.5) |
| Family income (n, %)             |                    |
| < Local average                  | 339 (6.5)          |
| Local average                    | 3651 (70.5)        |
| > Local average                  | 946 (18.3)         |
| Unknown                          | 245 (4.7)          |

**Table 2** Clinical characteristics of included patients

| Clinical characteristics          | Patients (n = 5181) |
|----------------------------------|--------------------|
| BMI (kg/m²), Mean ± SD           | 27.7 ± 6.0         |
| BMI group (n, %)                 |                    |
| < 24 kg/m²                       | 978 (18.9)         |
| 24–28 kg/m²                      | 2363 (45.6)        |
| ≥ 28 kg/m²                       | 1840 (35.5)        |
| Central Obesity (n, %)           | 3720 (71.8)        |
| Duration of NAFLD (mo), Mean ± SD| 36.8 ± 46.5        |
| Disease severity (n, %)          |                    |
| Simple fatty liver               | 4661 (90.0)        |
| NASH                             | 187 (3.6)          |
| Cirrhosis                        | 28 (0.5)           |
| Unknown                          | 305 (5.9)          |
| Complications (n, %)             |                    |
| Diabetes                         | 801 (15.5)         |
| Hypertension                     | 1191 (23.0)        |
| Hyperlipidemia                   | 1955 (37.7)        |
| Cardiovascular disease           | 414 (8.0)          |
| Depression                       | 135 (2.6)          |
| Colon disease                    | 115 (2.2)          |
| Duration of ongoing treatment (mo), Mean ± SD | 12.9 ± 25.9 |
| Laboratory examination, Mean ± SD|                    |
| ALT (U/L)                        | 53.2 ± 47.0        |
| TG (mmol/L)                      | 2.4 ± 2.1          |

**Table 3** Chronic Liver Disease Questionnaire score in overall and six domains

| Variable                                | Score (Mean ± SD) |
|-----------------------------------------|-------------------|
| Overall CLDQ score                      | 5.66 ± 0.89       |
| CLDQ domains                            |                   |
| Abdominal symptoms                      | 5.59 ± 1.07       |
| Activity                                | 5.73 ± 0.95       |
| Emotional function                      | 5.66 ± 0.98       |
| Fatigue                                 | 5.31 ± 1.10       |
| Systemic symptoms                       | 5.73 ± 0.92       |
| Worry                                   | 5.88 ± 1.00       |

NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; BMI, body mass index; SD, standard deviations; mo, months; ALT, alanine transaminase; TG, triglyceride
activity, 5.73 ± 0.95; emotional function, 5.66 ± 0.98; fatigue, 5.31 ± 1.10; systemic symptoms, 5.73 ± 0.92; worry, 5.88 ± 1.00).

Logistic regression analysis
Univariate analysis revealed that family income, education, residence, ALT, TG, BMI, disease severity, and clinical complications including diabetes, hypertension, hyperlipidemia, cardiovascular disease, depression, colon diseases (all \( p < 0.05 \)) were significantly associated with overall CLDQ score (Figs. 1 and 2). Multivariate logistic regression analysis showed that BMI (HR, 1.642; 95% CI, 1.330–2.026), ALT (HR, 1.006; 95% CI, 1.001–1.011), TG (HR, 1.184; 95% CI, 1.074–1.305), disease severity (HR, 3.203; 95% CI, 1.418–7.232), cardiovascular disease (HR, 4.305; 95% CI, 2.074–8.939) were independent risk factors for overall CLDQ score (Fig. 3).

In addition, univariate analysis revealed that education, residence, ALT, TG, BMI, disease severity, and clinical complications including diabetes, hyperlipidemia, cardiovascular disease, depression, colon disease were significantly associated with the CLDQ score of all domains (Figs. 1 and 2). Multivariate logistic regression analysis showed that BMI and TG were independent risk factors for the CLDQ score of all domains (Fig. 4). ALT, disease severity, diabetes, depression and cardiovascular disease were independent risk factors for the CLDQ score of several domains. Colon disease (HR, 4.095; 95% CI, 1.448–11.577) was the independent risk factor only for the CLDQ score of abdominal symptoms domain (Fig. 3a), while gender (HR, 1.721; 95% CI, 1.228–2.441) was the independent risk factor only for activity domain (Fig. 3b).

Discussion
Since the number of patients with NAFLD in China may account for half of the patients with NAFLD worldwide, it is necessary to explore not only clinical outcomes but also quality outcomes, especially patient-reported outcomes (PRO) [5]. Although many different PROs are analyzed, HRQL is one of the most important [15]. Exploring the impact of NAFLD on patients’ well-being and HRQL is helpful to improve their care management. In this national multicenter cross-sectional survey in China, poor HRQL were demonstrated in these patients with NAFLD. BMI, ALT, TG, disease severity and cardiovascular disease were independent risk factors for HRQL. The present study from China
may provide important evidence for expanding the knowledge about the effects of NAFLD on patients.

The study performed by Golabi et al. showed that 22% of patients with NAFLD reported that their health was poor or fair, which was significantly higher than that of the healthy control group (10%) [11]. Data from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) showed that subjects with NAFLD had worse physical and mental health scores compared to the U.S. general population (with and without chronic illness) [16]. Similarly, Dan et al. demonstrated that patients with NAFLD had significantly lower HRQL compared with patients with hepatitis B or hepatitis C [17]. In present study, we also found that the HRQL in Chinese patients with NAFLD was impaired on all CLDQ domains, with an overall CLDQ score of 5.66 ± 0.89, even although majority of patients with NAFLD included in our study were asymptomatic.

The present study showed that disease severity was significantly correlated with the CLDQ score in overall and six domains, and the CLDQ score (simple fatty liver, 5.67 ± 0.87; NASH, 5.17 ± 1.00; cirrhosis, 5.17 ± 1.02) decreased with the progression of NAFLD. Although our study may underestimate the severity of NAFLD due to the self-reported diagnosis and the limited application of liver biopsies during clinical practice of NAFLD in China, the same trend existed in all six domains. David et al. reported that patients who had progressed to NASH had lower HRQL scores than patients with simple steatosis, and patients with cirrhotic had the least HRQL scores [16]. Another study showed that patients with cirrhosis had lower quality of life and utility scores than non-cirrhotic patients, however mental health scores did not differ between participants with and without NASH [18]. The divergence between our and previous study may be result from the socioeconomic environment of different countries, different HRQL tools and inclusion criteria.

In present study, we also found that the HRQL of patients with NAFLD worsened with the increase of BMI, and BMI was independent risk factor of the CLDQ score in overall and six domains. This was consistent with previous study, which showed that obese children with NAFLD had worse total, physical and psychosocial health scores compared to healthy children [19]. Basing on the significant association of BMI and HRQL of patients
with NAFLD, some studies had tried to confirm the fact that the decrease of BMI could improve the impairment of HRQL [12]. Abdelbasset et al. indicated that an eight-week high-intensity interval aerobic exercise had a beneficial effect on weight loss and HRQL [20]. Hickman et al. also demonstrated that the HRQL of patients with NAFLD and HCV was significantly improved after weight loss [21]. Although patients with normal weight (BMI < 24 kg/m²), named as lean NAFLD, had highest CLDQ score than those of overweight (BMI 24–27.99 kg/m²) and obese patients (BMI ≥ 28 kg/m²), lean patients with NAFLD still had impaired HRQL according to our results. As previous studies had never reported the HRQL of lean patients with NAFLD yet, our results may provide some knowledge about the impairment of HRQL in these patients.

The key strength of the study is that this is a national multicenter HRQL survey of patients with NAFLD with a large sample size, which helps to obtain PRO information of patients with NAFLD in China. However, there are several limitations in the current study. Firstly, due to the large population of patients with NAFLD in China and most of them with no symptom, some patients may not be diagnosed, which makes it impossible to obtain the specific number of patients with NAFLD in China. Considering the feasibility of the study, the sample was selected via convenience sampling method and patients with NAFLD in 90 hospitals among 24 provinces in China were recruited consecutively from March 1 to August 1, 2019. Secondly, the CLDQ-NAFLD used in this study has not been well verified in China. However, CLDQ-NAFLD is still a better choice for us because it’s more specific for patients with NAFLD compared with CLDQ or Short Form 36-item Health Survey (SF-36). Thirdly, the validation population of CLDQ-NAFLD does not include patients with end-stage liver disease. In our study, only 28 patients with cirrhosis are included, but the number is too small to change the final results. Fourthly, the large sample size limits the performance of longitudinal follow-up. The lifestyle intervention, medicine and even surgery on improvement of HRQL of patients with NAFLD should form an important component of related studies in the future.
Conclusions

This national multicenter cross-sectional survey in China indicated that the HRQL in patients with NAFLD was impaired. Significant association between HRQL and sociodemographic and clinical factors were found in this study. Attention should be paid to the optimally managing care of patients with NAFLD to improve their HRQL. The present study from China may provide important evidence for expanding the knowledge about the effects of NAFLD on patients. Since this is a cross-sectional survey, a longitudinal study on the impact of disease progression and interventions on HRQL is need in the future.

Abbreviations

NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; HRQL: Health Related Quality of Life; CLDQ: Chronic Liver Disease Questionnaire; CT: Computed tomography; TG: Triglyceride; ALT: Alanine transaminase; BMI: Body mass index; SD: Standard deviations; PRO: Patient-reported outcomes.

Acknowledgements

Thanks to Sanofi for providing language editing services.

Authors’ contributions

Conception and design, RH, JL, HR and LW; Data analysis and interpretation, RH, HR and LW; Providing materials and samples, all authors; Drafting article, RH; Administrative support, JL. All the authors read and approved the final manuscript.

Funding

This work was supported by National Natural Science Foundation of China (number 81870406), Beijing Natural Science Foundation (number 7182174), and the China National Science and Technology Major Project for Infectious Diseases Control during the 13th Five-Year Plan Period (number 2017ZX1020202).

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Peking University People's Hospital (2018PHB259-01). Written informed consent was obtained from each patient.

Consent for publication

Not applicable.

Competing interests

HRao has received speaking fees from Bristol-Myers Squibb, Gilead, and AbbVie. L Wei has received research support and/or consulting fees from AbbVie, Bristol-Myers Squibb, Gilead, Roche, and Novartis. J Li serves for China Resources Sanjiu Medical and Pharmaceutical Co., Ltd. R Huang, J Fan, J Shi, Y Mao, B Wang, J Zhao, L Lu, B Zhong, Z Zou, Y Xu, Y Ye, L Liu and L Lin have no conflicts.

Author details

1 Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology On NAFLD Diagnosis, No.11 Xizhimen South Street, Beijing 100044, China. 2 Department of Digestive, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3 Department of Hepatology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China. 4 Department of Digestive, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 5 Department of Digestive, The First Hospital of China Medical University, Shenyang, China. 6 Department of Pathology, The Fifth Medical Center of PLA General Hospital, Beijing, China. 7 Department of Digestive, The First People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. 8 Department of Digestive, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. 9 Department of Digestive, Beijing TianTan Hospital, Capital Medical University, Beijing, China. 10 Department of Infectious Disease, The First Hospital of Fushan, Fushan, China. 11 Department of Hepatology, The Third People's Hospital, Changzhou, China. 12 Department of Digestive, Shengjing Hospital of China Medical University, Shenyang, China. 13 China Resources Sanjiu Medical and Pharmaceutical Co., Ltd, Shenzhen, China. 14 Hepatopancreatoobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, No.168, Litang Road, Changping District, Beijing 102218, China.

Received: 25 September 2020   Accepted: 22 April 2021

Published online: 07 May 2021

References

1. Zhou Y, Ding YL, Zhang JL, Zhang P, Wang JQ, Li ZH. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomed Pharmacother. 2018;97:1397–408. https://doi.org/10.1016/j.biopha.2017.10.035.
2. Pan SD, Chen XH, Shen HY, Li X P, Cai MQ, Zhao YG, et al. Retracted: Rapid and effective sample cleanup based on graphene oxide-encapsulated core-shell magnetic microspheres for determination of fifteen trace environmental phenols in seafood by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2019;1046:208. https://doi.org/10.1016/j.aca.2018.10.049.
3. Kim GA, Lee HC, Choe J, Kim MJ, Lee MJ, Chang HS, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017. https://doi.org/10.1016/j.jhep.2017.09.012.
4. Younossi ZM, Koenig AB, Abdelfat D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.
5. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology (Baltimore, MD). 2014;60(6):2099–108. https://doi.org/10.1002/hep.27406.
6. Safita N, Islam SM, Chow CK, Niessen L, Lechner A, Holle R, et al. The impact of type 2 diabetes on health related quality of life in Bangladesh: results from a matched study comparing treated cases with non-diabetic controls. Health Qual Life Outcomes. 2016;14(1):129. https://doi.org/10.1186/s12955-016-0530-7.
7. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 2017;37(8):1209–18. https://doi.org/10.1111/liv.13391.
8. Ferrer M, Córdoba J, Garín O, Olivé G, Fliviá M, Vargas V, et al. Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl. 2006;12(1):95–104. https://doi.org/10.1002/lt.20551.
9. Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000106. https://doi.org/10.1136/bmjgast-2016-000106.
10. Huber Y, Boyle M, Hallsworth K, Tinaiakos D, Straub BK, Labenz C, et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17(10):2085-92.e1. https://doi.org/10.1016/j.cgh.2018.12.016.
11. Gobati P, Otgonsuren M, Cilel C, Felix S, Koenig A, Sayiner M, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes. 2016;14:18. https://doi.org/10.1186/s12955-016-0420-z.
12. Tapper EB, Lai M. Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study. Hepatology (Baltimore, MD). 2016;63(4):1184–9. https://doi.org/10.1002/hep.28416.

13. Anyayo L, Ashaba S, Kaggwa MM, Maling S, Nakimuli-Mpungu E. Health-related quality of life among patients with bipolar disorder in rural southwestern Uganda: a hospital based cross sectional study. Health Qual Life Outcomes. 2021;19(1):84. https://doi.org/10.1186/s12955-021-01729-5.

14. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45(2):295–300. https://doi.org/10.1136/gut.45.2.295.

15. Kastien-Hilka T, Abulfathi A, Rosenkranz B, Bennett B, Schwenkglenks M, Sinanovic E. Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis - a systematic review of global literature with focus on South Africa. Health Qual Life Outcomes. 2016;14:42. https://doi.org/10.1186/s12955-016-0442-6.

16. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology (Baltimore, MD). 2009;49(6):1904–12. https://doi.org/10.1002/hep.22868.

17. Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S, et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;26(6):815–20. https://doi.org/10.1111/j.1365-2036.2007.03426.x.

18. Chawla KS, Talwalkar JA, Keach JC, Malinchoc M, Lindor KD, Jorgensen R. Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterol. 2016;3(1):e000069. https://doi.org/10.1136/bmjgast-2015-000069.

19. Kistler KD, Molloston J, Unalp A, Abrams SH, Behling C, Schwimmer JB. Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31(3):396–406. https://doi.org/10.1111/j.1365-2036.2009.04181.x.

20. Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Soliman GS. A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease. Medicine. 2019;98(12):e14918. https://doi.org/10.1097/md.00000000000014918.

21. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53(3):413–9. https://doi.org/10.1136/gut.2003.027581.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.